Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Janssen’s Stelara shows benefits for Crohn’s disease treatment

Janssen’s Stelara shows benefits for Crohn’s disease treatment

20th February 2017

Janssen has announced the findings of a new clinical trial that demonstrates the strong performance of Stelara in the treatment of Crohn's disease.

Two-year data from the ongoing IM-UNITI long-term extension study has highlighted the efficacy and safety of subcutaneous Stelara in adult patients with moderate to severely active Crohn's disease, with the drug maintaining clinical response and remission rates for up to two years.

No new safety signals were observed in the study, which enrolled 1,281 patients in total. The new data was recorded 96 weeks after subjects commenced their treatment.

Crohn's disease is an incurable condition associated with abnormalities of the immune system that leads to abdominal pain and tenderness, frequent diarrhoea, rectal bleeding, weight loss and fever.

Frederic Lavie, Janssen's European therapeutic area leader for immunology, cardiovascular and metabolics, said: "We look forward to sharing future results from the UNITI programme, and remain committed to improving overall outcomes for people living with Crohn's disease."

Stelara is currently approved for the treatment of Crohn's disease sufferers who are unable to benefit from other forms of therapy.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801832553-ADNFCR

We have hundreds of jobs available across the Healthcare industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.